Opioid dependence is epidemic in the United States. While progress has been made in training providers, the gap in providing effective treatment of opioid use disorders continues to widen – moving beyond heroin addicted individuals to a much larger and diverse segment of the population. This increase in predominantly due to an alarming increase in addiction to prescription opioid analgesic medications.
Buprenorphine, the most recent addition to the pharmacotherapies available to treat opioid dependence, is novel among the opioid pharmacotherapies because of its partial agonist properties. It has been placed on Schedule III and is available by prescription from a physician’s office-based practice.
Recognizing the impact of this addiction, as well as learning how to treat opioid use disorders, are important steps in combating this ever growing medical problem. To obtain the waiver to prescribe, providers are required to take specialized training. PCSS-MAT uses the Half-and-Half format (first, 4.25 hours of face-to-face training with an instructor, followed by 3.75 hours of on-your-own training that must be completed along with a post test). This meets the training requirements for physicians; however, additional training is required for advanced practice providers.
The training focuses on the specifics of treating patients with opioid use disorders in office-based settings and clinical vignettes to help trainees think through “real life” experiences in opioid use disorders treatment. Once the waiver training is completed in full, participants will receive a CME certificate of attendance from AAAP.
- Define the federal Drug Abuse Treatment Act (DATA) of 2000 and the subsequent revisions that list the criteria needed for Office Based Opioid Treatment (OBOT)
- List the criteria for establishing a diagnosis of opioid dependence.
- Distinguish between spontaneous withdrawal and precipitated withdrawal and the appropriate methods of buprenorphine induction.
- Describe and contrast the functions of full mu agonists, partial agonists and antagonists.
- Explain the interplay between pain and addiction and how buprenorphine can be used to help stabilize these patients.
- Describe the basic approach used in at least three different types of non-pharmacological treatments of opioid dependence.
- Describe three symptoms of opioid withdrawal or intoxication that mimic symptoms of a psychiatric disorder.
- Describe at least three factors to consider in determining if the patient is an appropriate candidate for office-based treatment with buprenorphine.
- Describe at least three areas that should be covered in the rules and expectations communicated to patients during the patient assessment process.
- List at least three situations in which patient information, with patient identity, can be shared under current laws protecting the patient’s confidentiality 42 CFR and HIPAA
- Reduce and minimize buprenorphine misuse and diversion.
- Describe the drug interactions of buprenorphine and pediatric exposures.
Click here for a brochure